Suzanne Hodsden

Suzanne Hodsden is a contributor who writes regular life sciences news features for several publications. She holds degrees from Denison University and Bowling Green State University.

  • Llamas Could Hold The Cure For HIV

    A collaboration between the University College London (UCL) and the Scripps Research Institute has found antibodies in the immune systems of llamas, which have the potential to create a HIV vaccine, Tech Times reports.

  • Curie-Cancer, GamaMabs Renew Collaboration For Biologic Ovarian Cancer Drug

    GamaMabs Pharma, a biotech specializing in the development of biologic cancer drugs, announced the extension of their collaboration with Curie-Cancer, a leading academic research institute.

  • U.K., U.S. Collaboration Seeks To Repurpose Drugs As Neurological Treatments

    U.S. non-profit, Alzheimer’s Drug Discovery Foundation (ADDFF) and the Alzheimer’s Society U.K. (ASUK) announced they would be funding two separate clinical trials to establish alternate proof of concept and potentially repurpose two pipeline medications indicated for separate illnesses. One study will test the efficacy of an erectile dysfunction (ED) medication against vascular dementia, and the other will test a diabetes medication as an Alzheimer’s treatment.

  • AMR Superbugs Could “Cast Medicine Back To The Dark Ages,” Says Study

    A new study commissioned by the British government estimates that by 2050, antimicrobial- resistant (AMR) disease could take 10 million lives per year and rack up a global cost of over $100 trillion. The figures reinforce the importance of investment in new, effective AMR drugs, Reuters reports.

  • Potential Treatment For Drug-Resistant Skin Cancer Discovered

    The Wellcome Trust and Cancer Research UK have co-funded a study that has discovered potential skin cancer drugs which can multi-task and prove more potent than existing melanoma treatments.

  • Ono Pharma, Bristol-Myers Squibb, Kyowa Hakko Kirin Collaborate On Immuno-Oncology Drug Study

    Three companies are combining their efforts on a new immuno-oncology drug study that will test the efficacy of using Opdivo and mogamulizumab together to treat advanced or metastatic solid tumors.

  • Harvard Research Finds Potential 3D Cancer Vaccine

    Researchers at Harvard University have discovered a way to inject programmable biomaterial which assembles into 3D structures after the injection.

  • New Drug Development Alliance Formed To Tackle Multiple Sclerosis

    French-based pharmaceutical research company, Servier has invested an initial $47 million in GeNeuro for the development of GNbAC1, a biologic candidate undergoing testing as a multiple sclerosis (MS) therapy which currently in phase 2b testing.

  • Recipharm Acquires Flamel Facility As Part Of $26M Deal

    Swedish CDMO Recipharm and French-based Flamel Technologies announced a long-term collaboration in which Recipharm will purchase Flamel’s Pessac facility and Flamel stock, and take over several new development and manufacturing contracts. The current financial deal is worth $26 million with the option of additional contracts.

  • Eisai Expands Manufacturing In Asia And Europe

    Japan-based Eisai has opened two new manufacturing facilities, one in Suzhou, Jiangsu China and the other in the U.K. Investment in the new space is expected to improve Eisai’s supply chain and production efficiency. Eisai did not release the financial details of either investment.